Johnson & Johnson's Two-Drug Combo Shows Promise in Advanced Multiple Myeloma

Johnson & Johnson's two-drug combination therapy has demonstrated significant promise in treating advanced multiple myeloma, according to results from a Phase 3 study presented at the recent American Society of Hematology meeting.

The study revealed that this regimen blocked tumor progression more effectively than the standard of care for patients suffering from relapsed or refractory multiple myeloma. This advancement highlights the potential of combination therapies in providing new hope for patients facing this challenging disease.